Adlai Nortye Strikes Global Clinical Collaboration with Lilly and Merck for AN4035 Combination Trial

Adlai Nortye (ANL) has partnered with Lilly and Merck KGaA for a global Phase I trial of AN4035, a CEACAM5-targeting ADC. Lilly and Merck will supply cetuximab for free. ANL's stock has a Buy rating with a $31 target, but Spark rates it Neutral due to financial risks and bearish trends. ANL focuses on precision oncology, targeting RAS-addicted cancers.

Original reporting
Published Oct 15, 2026, 11:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ANL
Bullish
medium confidence
Mentioned
$ANL · $MRK
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$ANLBullishLow
01

Why it matters

The new supply agreements with Lilly and Merck reduce trial costs and add validation, potentially improving the company's valuation outlook.

02

Market read

First‑time disclosure of a multi‑partner clinical collaboration for ANL's lead ADC, a material catalyst for the micro‑cap biotech.

03

What to watch

No disclosed financial terms; the partnership could be more about data generation than immediate revenue.

Relevance 8/10Novelty 8/10Timing: today

Background

Adlai Nortye (ANL) is a clinical‑stage biotech focused on CEACAM5‑targeted ADCs and RAS pathway inhibitors.

Company-level read

Ticker impact

$ANLBullishMedium confidence
Context

Adlai Nortye announced new clinical‑trial collaboration and supply agreements with Eli Lilly and Merck for its AN4035 ADC program.

Expected impact

possible modest upside as investors price in the added validation from major pharma partners

Evidence & confidence

The deal is a fresh, material development for a micro‑cap biotech, but no immediate financial impact or price target change is disclosed.

Market effects

Adds credibility to the ADC and RAS‑targeted oncology sector, may encourage peer interest.

Limited to U.S., Australian and Chinese oncology trial markets.

Modest; primarily relevant to biotech investors.

Counterpoint

The collaboration may not translate into commercial success; trial risks remain high for early‑stage ADCs.

Key entities

  • Eli Lilly and Company

    Provides cetuximab at no cost for U.S. trial sites.

  • Merck KGaA

    Supplies cetuximab for Australian and Chinese trial sites.

Related articles

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$MRKMed

Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns

Merck (MRK) is discontinuing development of nemtabrutinib, an experimental BTK inhibitor acquired via its $2.7B purchase of ArQule, due to safety concerns identified in late-stage trials. The decision follows recommendations from a data monitoring committee and Merck's own review, leading to the halt of several Phase 3 studies in the BELLWAVE program. The drug was being evaluated for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

$MRKLow

Merck names Douglas Baker as independent lead director

Merck & Co. (NYSE: MRK) announced Douglas M. Baker, Jr. will become independent lead director of its board, effective January 1, 2027. Baker, who has served on the board since 2022, will succeed Thomas H. Glocer. Merck's CEO Rob Davis praised Baker's leadership experience. The announcement was made on Wednesday.

$MRKMed

MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib

MSD (Merck & Co) halted its Phase III BELLWAVE-011 trial of nemtabrutinib for leukaemia after an external review found potential risks outweighed benefits. The company also terminated the wider BELLWAVE program, including two other Phase III trials. MSD plans to share full findings and continue developing treatments for blood cancers. According to GlobalData, CLL/SLL cases in major markets are expected to rise to 478,279 by 2032.